CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hydration Pharmaceuticals Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hydration Pharmaceuticals Co Ltd
Level 2,, 6 Palmer Parade,, Cremorne
MELBOURNE, VIC  3121  Australia Ticker: HPCHPC
Business Summary
The Hydration Pharmaceuticals Company Limited is an Australia-based hydration solutions company. The Company is focused on the sale and distribution of Hydralyte, which includes a product range of electrolyte-rich tablets, liquids, and powders. The Company markets and sells a range of liquid, tablet, and powder healthy hydration solutions products in the North American markets of Canada and the United States, under the Hydralyte brand. The Company operates as a wholesale supplier and online retailer of Hydralyte products in North America. The Company has a sales footprint in various markets, including the United States, Canada, Australia, New Zealand, Asia (excluding China, which includes Hong Kong but excludes Taiwan), Africa and the Middle East (excluding Turkey). Its subsidiaries include Hydration Pharmaceuticals Trust, Hydration Pharmaceuticals Canada, Hydralyte LLC, and others.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Chairman of the Board AdemKarafili 5/25/2024 10/15/2018
Chief Executive Officer, Managing Director OliverBaker 5/25/2024
Chief Financial Officer ChrisKavanaugh 5/1/2018
3 additional Officers and Directors records available in full report.

Business Names
Business Name
HPC
HPCXX

General Information
Outstanding Shares: 304,913,073 (As of 6/30/2024)
Stock Exchange: ASX


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, December 2, 2024